New victims of current drug laws.
New victims of current drug laws.
复制标题
现行禁毒法的新受害者。
DOI：
10.1038/nrn3530-c2
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Nutt DJ
中科院分区：
文献类型：
--
作者：
Nutt DJ
在他们对我们的文章（附表一药物法对神经科学研究和治疗创新的影响。Nature Rev. Neurosci. 14，577-585（2013））1，Stewart和Kalueff（Controlled substances and innovation of biomedicine：a preclinical perspective. Nature Rev. Neurosci. http：//dx. doi。org/10.1038/nrn 3530-c1（2013））2提供了对当前药物法给研究人员带来的负担的额外见解。他们的经历增加了我们收到的许多电子邮件，支持采取更合理的监管方法的呼吁。自我们的第1条发表以来，联合王国出现了若干事态发展。积极的一面是，英国内政部已澄清，2-溴-LSD（麦角酸二乙基酰胺）不受附表1管制，这应有助于研究这种药物作为治疗丛集性头痛的药物。然而，在通过修订1971年英国滥用药物法公布之前，科学家和执法人员都不会清楚地看到这一点。另一方面，一项新的临时管制药物令（TCDO）3现在将几种MDMA类似物列入附表1，包括6-APB（也称为6-（2-aminopropyl）benzofuran）和其他正在开发的用于治疗帕金森氏病运动障碍的新药物。这已经阻碍了--而且可能会终止--这些化合物的开发，因为对那些被列为管制药物的化合物几乎没有商业兴趣。相同的TCDO适用于一系列NBOMe化合物，从而无意中禁止了用于血清素系统的最有前途的正电子发射断层扫描（PET）配体-即[11 C] Cimbi-36（也称为25 I-NBOMe和2（4-碘-2，5-二甲氧基苯基）-N-（（2-甲氧基苯基）甲基）乙胺）-即使PET研究中使用的剂量没有主观影响4。
In their response to our article (Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Rev. Neurosci. 14, 577–585 (2013)) 1, Stewart and Kalueff (Controlled substances and innovation of biomedicine: a preclinical perspective. Nature Rev. Neurosci. http://dx. doi. org/10.1038/nrn3530-c1 (2013)) 2 provide additional insights into the burden that is placed on researchers by the current drug laws. Their experiences add to the many e-mails we have received supporting the call for a more rational regulatory approach. Since our article 1 was published, there have been several developments in the United Kingdom. On the positive side, the UK Home Office has clarified that 2-bromo-LSD (lysergic acid diethylamide) is not Schedule 1-controlled, which should facilitate research into this drug as a treatment for cluster headaches. However, until it is made public by revising the UK Misuse of Drugs Act 1971, this clarification will not be apparent either to scientists or law enforcers. A similar request for a clear evidence-based decision on the legal status of tetrahydrocannabivarin has not been answered.On the negative side, a new temporary control drug order (TCDO) 3 now places several MDMA analogues under Schedule 1, including 6-APB (also known as 6-(2-aminopropyl) benzofuran) and other compounds that are being developed as new treatments for dyskinesias in Parkinson's disease. This has impeded—and will probably end—the development of these compounds because there is little commercial interest in compounds that are scheduled as a controlled drug. The same TCDO applies to a series of NBOMe compounds, thereby inadvertently banning the most promising positron emission tomography (PET) ligand for the serotonin system—namely,[11 C] Cimbi-36 (also known as 25I-NBOMe and 2 (4-iodo-2, 5-dimethoxyphenyl)-N-((2-methoxyphenyl) methyl) ethanamine)—even though the doses used in PET studies have no subjective effects 4.